In summary, we uncover a miR22–MYC signaling loop in MM, in which miR-22 functions as a pivotal antitumor gatekeeper by direct cytotoxic activity and/or by immune-mediated activity. This evidence concerns the gene MYC and Miyoshi myopathy.